Search results for: 'security screening systems xaas global'

The global small‑molecule CDMO industry is undergoing a structural transformation driven by increasing molecular complexity, patent expiries, cost pressures, and the strategic need to secure resilient pharmaceutical supply chains. Demand is shifting beyond high‑volume commodity generics toward specialized development and manufacturing capabilities ...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations reshaping drug discovery, diagnostics, and therapeutic delivery across oncology, infectious diseases, rare and autoimmune disorders, metabolic and age-related conditions, neurodegenerative and neuromu...

In this analysis, Frost & Sullivan identifies and defines the leading trends shaping the global pharmaceutical landscape. The study period is 2022–2030, with 2024 as the base year and 2025–2028 as the forecast period. The geographic scope includes 5 regions: North America, Latin America (LATAM) and the Caribbean, Asia-Pacific (APAC), Europe, and th...

15 May 2025  |  Global  |  Market Research

Immunomodulator Therapeutics Market, Global, 2024–2030

Mechanism-targeted Approaches are Driving Transformational Growth by Enabling Innovation in Autoimmune, Oncology, and Inflammatory Therapies

Infographics

×

This research service offers a comprehensive analysis of the global immunomodulator therapeutics market, specifically targeting inflammatory disorders in the immunology, gastrointestinal (GI), and dermatology segments. The report defines this market through products designed to modify and regulate pathological immune responses, either by inhibiting...

20 Nov 2017  |  North America  |  Market Research

Global Biologics Market—Companies-to-Action

Biopharma Companies are Increasingly Collaborating with CDMOs, CROs, and Digital and Medical Equipment Companies for Biologics Discovery and Development

Infographics

×

This study on the "Global Biologics Market: Companies-to-Action" presents an overview of the global biologics landscape with an emphasis on the top 10 leading bio-pharma companies in the market. The study highlights the shifting focus and investments of bio-pharma companies towards biologics discovery and development, which is attributed to the gro...

The biopharma industry has been evolving over the past few decades. This study analyses the top ten trends that will impact the future of the biopharma industry through 2040.The future of biopharma will be driven by innovation in AI and ML, particularly generative AI, and by advancements in translational medicine and synthetic biology. Future clini...

The US and European mammalian contract development and manufacturing organization (CDMO) market is entering a new phase of strategic evolution, driven by accelerating biologics outsourcing, increasing molecule complexity, and growing demand for resilient, end-to-end manufacturing partnerships. As monoclonal antibodies, bispecific antibodies, Fc-fus...

16 Aug 2016  |  North America  |  Market Research

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Emerging Business Models Drive Transformation

Infographics

×

The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients (APIs) and intermediates; and finished dose formulations (FDFs), further segmented by solid, liquid and semi-solid, and injectable doses—and to understand the value chain from clinical to comme...

21 Mar 2025  |  Global  |  Market Research

Pharmaceutical Clinical Contract Peripheral Services, Global, 2025–2030

The CRO Industry is Witnessing Transformational Growth Due to Industry Convergence and an Increasing Reliance on the Functional Service Provider (FSP) Model

Infographics

×

As trial volumes normalize after the COVID-19 pandemic, pharma and biopharma companies are re-focusing on their drug development pipelines. As a result, the market has been creating an increasing number of clinical trial outsourcing opportunities for CROs, with these service providers also refining their processes to ensure better clinical trial tu...